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ABSTRACT. Non-invasive bioimaging techniques are critical for assessing the biodistribution of 
cellular therapies longitudinally. Among them, photoacoustic imaging (PAI) can generate high 
resolution images with tissue penetration depth of ~ 4 cm. However, it is essential and still highly 
challenging to develop stable and efficient near infra-red (NIR) probes with low toxicity for PAI. 
We report here the preparation and use of perylene diimide derivative (PDI) with NIR absorbance 
(around 700 nm) as nanoprobes for tracking mesenchymal stromal cells (MSCs) in mice. 
Employing an in-house synthesized star hyperbranched polymer as stabilizer is the key to the 
formation of stable PDI nanoparticles with low toxicity and high uptake by the MSCs. The PDI 
nanoparticles remain within the MSCs as demonstrated by in vitro and in vivo assessments. The 
PDI-labelled MSCs injected subcutaneously on the flanks of the mice are clearly visualized with 
PAI up to 11 days post-administration. Furthermore, bioluminescence imaging of PDI-labelled 
luciferase-expressing MSCs confirms that the administered cells remain viable for the duration of 
the experiment. These PDI nanoprobes thus have good potential for tracking administered cells in 




Cell-based regenerative medicine therapies (RMTs) are being explored as treatments for the 
diseases of different types. Mesenchymal stromal cells (MSCs) have been the most widely used 
RMT, but despite showing therapeutic effects in a range of animal disease models, the results of 
most clinical trials have so far been disappointing.1-4 Due to the challenges of monitoring the fate 
of administered cells, it is not clear if this lack of efficacy in the clinic is due to the cells not 
reaching their target, or their failure to persist in the target organ.  A further problem with cell-
based RMTs is the risk of tumourigenicity.5-7 Strategies that assess the growth, function, and 
biodistribution of administered cells longitudinally in vivo would allow better understanding of 
their behavior and mechanisms of action, potentially facilitating the development of safer and more 
efficacious treatments.5,7 
A number of non-invasive techniques have been employed to monitor cells in vivo, but all 
have some limitations.5,8 For instance, magnetic resonance imaging (MRI) can generate images 
with good spatial resolution but low temporal resolution, making it difficult to perform whole body 
scans. Fluorescence imaging (FI) has good temporal resolution but poor sensitivity, making it 
difficult to detect small numbers of cells. Bioluminescence imaging (BLI) has much greater 
sensitivity but poor spatial resolution, making it difficult to determine the precise location of the 
cells.5 Photoacoustic imaging (PAI) is a technique that can potentially address the shortcomings 
of the imaging methods mentioned above.9 This is because PAI exhibits high sensitivity, can image 
small numbers of cells in high tissue depth, and generate images of good spatial and temporal 
resolution. This makes it possible do whole body imaging of small cells.5,9 Near infrared (NIR) 
light is used in PAI to illuminate tissue and detect generated ultrasound wave (which have much 
lower scattering tendency by biological media and tissue than photons).8,10 This allows the 
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visualisation of targeted tissues and sub-organ structures at several centimeters of depth. With PAI, 
it is possible to image the entire depth of a mouse or tissues close to skin surface for large animals 
and human being. In general, PAI instruments operate as follows: when tissue is illuminated with 
NIR light, photo-absorbers present within the tissue absorb the light and undergo thermoelastic 
expansion, generating acoustic waves that can be detected at the body surface.9,10 Multispectral 
Optoacoustic Tomography (MSOT) is one type of PAI. MSOT utilizes multiple excitation 
wavelengths and allows multiple photo-absorbers to be identified simultaneously.11,12 Thus, 
MSOT is capable of imaging at multiple wavelengths and the information obtained from multiple 
wavelengths improves image accuracy. Each of the multiple photo-absorbers can be identified by 
spectrally unmixing, providing detailed information about the imaged subject.11-13 
Endogenous chromophores and exogenous contrast agents have been used as photo-absorbers 
for PAI.10, 14-15 These chromophores are good probes for PAI because they absorb light within the 
NIR region (approximately NIR-I window for 700 – 1000 nm and NIR-II window for 1000 – 1700 
nm) which shows less tissue absorption & photon scattering and lower levels of 
autofluorescence.10, 15-17 Endogenous chromophores include haemoglobin, lipid, and melanin, and 
genetically engineering chromophores or reporter genes (which can be expressed in situ over a 
long period, and is highly useful for longitudinal studies).10,14 Exogenous contrast agents are 
employed to improve PAI image contrast for various targeted applications. Exogenous PA contrast 
agents can be divided into molecules (mainly organic dyes including cyanine dyes, phthalein and 
xanthene dyes, squaraine and coroconaine dyes, etc.)18 and nanostructured materials.16, 19-20 Many 
types of nanostructure materials have been fabricated and investigated for PAI, which may be 
classified into inorganic materials (including metal (mostly gold) nanoparticles,17 semiconducting 
nanomaterials, carbon nanostructures, quantum dots), organic nanomaterials (including 
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semiconducting and conjugated polymer nanoparticles),21-24 and hybrid nanocomposites.10,16,20 
While inorganic materials as PAI nanoprobes are highly stable and produce bright images, organic 
nanoprobes can offer reduced toxicity (e.g., no heavy metals) and the flexibility in material 
functionality and light absorbance wavelength via chemical synthesis.21-24 
Perylene diimide (PDI) derivatives are one type of small molecule dyes which are extensively 
used in pigment and optoelectronics industries.25-26 They can be readily modified at the bay 
positions or by core expansion to induce fluorescence and NIR absorption with high quantum yield 
and high photostability.27-29 Furthermore, the solubility of PDIs in different solvents can be 
achieved by modifying groups at the imide positions and/or inducing bulky substitutes to the bay 
positions.29-30 Due to their design and synthetic potential, both hydrophobic and water-soluble 
PDIs with NIR absorbance have been used for PAI and photothermal treatment of cancer cells.31 
Examples include the use of hydrophobic PDI nanoparticles,32 64Cu-labeled amphiphilic PDI 
nanoparticles,33 zwitterionic PDI nanoparticles,34 and self-assembled terrylenediimide (TDI)-
based & quaterrylenediimides (QDI) nanoparticles.35,36 
In spite of the exciting use of NIR-absorbing PDI for PAI and photothermal treatment of 
cancer cells, as far as we are aware, the use of PDI nanoparticles for cell labelling has not been 
reported. Cell tracking, which follows specific cells in vivo and aims to determine cell location, 
fate, functionality or differentiation, is critical for optimizing cellular therapies including stem-
cell treatment as well as adoptive immunotherapy.37,38 Various non-invasive imaging techniques, 
for example, MRI, FLI, BLI, positron emission tomography (PET), have played key roles in cell 
tracking.37-39 Due to its potential in producing high resolution images with high tissue depth, PAI 
has begun to be used as a promising technique for cell tracking.39-43 Gold nanostructures have 
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been the main contrast agents for use in tracking cells by PA40,41,43 whilst semiconducting 
polymer nanoparticles were also used in labelling and tracking stem cells.42 
In this study, the potential of PDIs with NIR-absorbing properties was investigated as 
imaging probes to enable cell tracking with MSOT. As previously demonstrated,27-36 PDI 
nanoparticles are photostable, have a high extinction coefficient, feasibility of varying 
absorbance wavelength by changing synthesis conditions, and do not comprise heavy metals. 
PDIs, in the form of self-assembled structures or nanoparticles, have been used as photoacoustic 
probes in various fields. However, PDI nanoparticles can be highly effective for in vivo cell 
tracking, due to their unique photostability and high sensitivity/intensity over a longer imaging 
period. Herein, hydrophobic PDI nanoparticles were prepared in aqueous medium by a 
nanoprecipitation approach with the use of in-house synthesized star hyperbranched polymer 
(SHBP) as the biocompatible polymeric surfactant.44 We demonstrated that these PDI 
nanoparticles could label mouse MSCs and enable them to be tracked in vivo for 11 days with 
MSOT following subcutaneous injection in mice.  Moreover, by using a bimodal MSOT-BLI 
strategy, we confirmed that the PDI-labelled MSCs remained viable following in vivo 
administration. 
2. EXPERIMENTAL SECTION 
2.1. Materials. All chemicals and solvents were bought from Sigma Aldrich or Fisher and 
used as received. The star hyperbranched polymer (SHBP) (DEAEMA50-c-DEGDMA2)-b-
(OEGMA80) was synthesized in the group (see Supporting Information).
44 
2.2. Synthesis of PDI nanoparticles. Perylenetetracarboxylic dianhydride (PTCDA) was 
used as the starting material. Brominated PTCDA was firstly synthesized (Scheme S1), following 
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a previously report method with modifications.45 Brominated PTCDA was then used to synthesize 
the NIR-active PDI.46 All the PDIs were purified by column purification and recrystallization (see 
Supporting Information). 
PDI solution in acetone (1 mg/ml) was firstly prepared. A second solution was then prepared 
with PVA or the SHBP (DEAEMA50-c-DEGDMA2)-b-(OEGMA80) in acetone (2 mg/ml). These 
solutions were combined to achieve PDI:SHBP ratios of 1:1, 1:2 and 2:1 and made up to a volume 
of 2 ml with acetone. The acetone solution was then added to water (8 ml) in a dropwise manner 
while the water phase was stirred. The solution was stirred for 24 hours to allow the acetone to 
evaporate, yielding a clear, green aqueous nanoparticle suspension. No observation of large 
particles and colourless & transparent liquid phase after centrifuging with speed of 13,000 rpm 
indicated high yield of PDI nanoparticle formation. It should be pointed out that the observation 
was only qualitative. The calculation of encapsulation efficiency and loading content could be 
performed via the quantification of PDI in the nanoparticles by dissolving the PDI nanoparticles 
in acetone and subsequent UV-Vis absorption analysis. 
1H and 13C NMR spectra of PDIs were recorded in CDCl3 using a Bruker Fourier 300HD 
NMR spectrometer. Elemental analysis was performed using a ThermoFlash EA 112 series 
instrument and a µ–Quant Microplate reader was used to obtain UV-Vis absorption spectra after 
filtering the suspensions using a 0.22 µm syringe filter. Particle size was measured using a Malvern 
Zetasizer.  
2.3. Cell cytotoxicity and uptake of PDI nanoparticles. The evaluations of cell cytotoxicity 
were carried out by the ATP (adenosine triphosphate) assay on mesenchymal stromal cell line 
(mMSC D1, CRL-12424) which was obtained from ATCC and transduced with lentiviral particles 
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encoding firefly luciferase (Fluc) and ZsGreen or just ZsGreen under control of the constitutive 
promoter EF1a. MSCs were cultured in the medium comprised of Dulbecco’s Modified Eagle 
Medium (DMEM, D6546, Sigma Aldrich), 10% fetal bovine serum (FBS, Gibco), 2mM L-
glutamine (Sigma), 1% non-essential amino acids (Thermo Fisher), 0.1 mM 2-mercaptoethanol 
and 1% pen-strep at 37 °C under a humidified atmosphere with 5% CO2. The CellTiter-Glo® assay 
(the commercial kit for ATP assay) was used to assess cell viability; MSCs were placed in a 
standard 96-well plate (2 x 105 cells/well) and left to attach and grow for 24 hours. After this, the 
culturing medium was replaced with fresh medium (200 µl) containing various concentrations of 
PDI nanoparticles (0-36 μg/ml). The assay was performed after incubating the MSCs for another 
24 hours. To assess the effect of the PDI nanoparticles on MSC proliferation, cells were removed 
from the wells and counted using an automated cell counter (TC10, Biorad) at the culturing time 
of 24 h, 48 h, and 72 h. Confocal images were taken of fixed cell samples by Zeiss LSM 800 
Airyscan. The flow cytometry analysis was carried out on live cell suspensions using a BD 
FACSCalibur. (See Supporting Information for more details on cell fixing, MSCs expressing 
ZsGreen, Mitomycin-C treatment, and flow cytometry). 
2.4. In vivo Imaging. MSOT imaging of PDI-labelled MSCs in Agar phantoms was 
performed first (see Supporting Information for details on preparation of phantoms). For in vivo 
imaging, MSCs were labelled with 15 µg/ml PDI nanoparticles for 24 hours. 1 x 106 MSCs were 
then suspended in 150 μl phosphate-buffered saline (PBS). The cell suspensions (1 x 106, 0.5 x 
106, 0.25 x 106 PDI-labelled MSCs and 1 x 106 non-labelled MSCs) were then injected 
subcutaneously into four locations in the flanks of the mouse under anaesthetic condition. The 
immune-compromised nude CD1 mouse strain (female mice of 6-8 week old, bought from Charles 
River, UK) were used.  The mice were imaged three times (day 1, day 7, day 11). Whole body 
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scans were performed with 1 mm steps in a rostro-caudal direction. 26 wavelengths (660 nm – 900 
nm) were used for acquisition of images. On day 11 after the final imaging session, the mice were 
culled according to the Home Office guidelines. 
All animal experiments were carried out under a license granted under the Animals (Scientific 
Procedures) Act 1986 and were approved by the University of Liverpool ethics committee. MSOT 
imaging was carried out using an inVision 256-TF small animal imaging system (iThera Medical 
GmbH) under anaesthetic condition for about 30 minutes, followed by imaging using the IVIS 
Spectrum (for bioluminescence and fluorescence measurements) for about 5 minutes under the 
same anaesthetic session. All photoacoustic data were reconstructed and multispectrally processed 
to unmix for the PDI spectra using ViewMSOT software. 
2.5. Histology. Following animal sacrifice (on day 11), the MSC masses (visible to the 
naked eye) were surgically removed from the animals, fixed with 4% paraformaldehyde (24 h, 
4°C), washed with PBS and soaked overnight in 30% sucrose (4°C). The tissues were cryo-
embedded in OCT (Thermo Fisher) with dry ice and isopropanol, and stored at -80°C. Frozen 
cryostat sections were prepared by cutting at 7 µm thickness and stored at -20°C. Alizarin Red 
was then used to stain the MSC masses in order to detect the presence of calcium and check the 
potential of bone cell differentiation (see Supporting Information).  
 
3. RESULTS AND DISCUSSION 
3.1 Synthesis of PDI with NIR absorbance. PTCDA was used as the starting compound 
for the synthesis of NIR-active PDI. PTCDA is a highly hydrophobic dye and shows low 
solubility in most common solvents. In order to prepare the PDI with NIR absorbance and 
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suitable solubility, it is necessary to modify the PTCDA at the bay positions and the imide 
positions.29, 30 Halogenated PDIs are effective starting building blocks for various PDIs. 
However, halogenation at the bay positions (usually with Br2 or Cl2) is generally performed in 
concentrated sulfuric acid at elevated temperatures.25,29 Despite the harsh reaction conditions, a 
mixture of 1, 7-dihalogenated and 1, 6-dihalogenated perylene-based compounds is produced. 
We followed a method developed by Jager and co-authors to prepare regioisomerically pure 
brominated PTCDA under mild conditions,45 which was then used to produce the PDI with NIR 
absorbance and better solubility in organic solvents including dichloromethane and acetone,46 as 
shown in Figure 1 and Scheme S1. 
 
Figure 1. (a) The synthesis scheme for the preparation of the PDI with NIR absorbance 






methyl-2-pyrrolidinone with acetic acid, 85 oC, N2, 6 h. (iii) Pyrrolidine, N2, 48 h, 65 °C. (b) 
1H 
NMR spectrum of the PDI (always referred to compound 4 if not specified). (c) UV-Vis profiles 
of the PDI solutions in different organic solvents with the same concentration (0.05 mg/ml). 
 
Following the scheme illustrated in Figure 1a, the synthesis of compound 2 and the 
intermediate compounds is confirmed primarily by 1H NMR spectroscopy with additional 
information from 13C NMR and mass spectroscopy (Figures S1 – S3). The imide positions of 
compound 2 were then modified with cyclohexylamine to improve solubility in common 
solvents, followed by bay substitution of the bromine groups with pyrrolidine to achieve an NIR-
absorbing PDI derivative 4.46 
The 1H NMR spectrum confirms the formation of the PDI (compound 4, Figure 1b). 
Compared to compound 3 (Figure S4), the broad peaks at 3.8 ppm and 2.8 ppm are caused by the 
two differing hydrogen environments on the pyrrolidine rings. Some small peaks on the spectrum 
can be attributed to the impurities, which are still present after the recrystallization procedure. This 
is also reflected by the discrepancy of the elemental analysis data between the measured and 
calculated values of the PDI (Measured: C, 72.55%; H, 6.16%, N, 6.86%; Caculated: C, 76.25%; 
H, 6.42%; N, 8.09%). There is an obvious colour change from compound 3 to compound 4 – from 
orange red to dark green. This is also evidenced by the change of absorbance wavelength, i.e., the 
red shift from 528 nm to ~ 700 nm in dichloromethane (Figure S5).   
The PDI (compound 4, which is referred as ‘PDI’ from now on) was found to show much 
better solubility in organic solvents including dichloromethane, acetone and cyclohexane (Figure 
1c). The shapes of the UV-vis profiles are similar, but the peak positions are shifted for different 
solvents. Different absorbance intensity with the same concentration indicates different 
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absorbance coefficients. The strongest absorbance peaks of these solutions fall in the NIR region, 
with the wavelength being 662 nm for cyclohexane, 685 nm for acetone, and 695 nm for 
dichloromethane (DCM). This shows the PDI compound synthesized has the potential for PAI. 
 
3.2. PDI nanoparticles. PDI is a hydrophobic compound and has very low solubility in water, 
hence cannot be used directly for bioimaging. However, it is possible to prepare an aqueous PDI 
nanoparticle suspension which can then be used for bioimaging. Aqueous organic nanoparticle 
suspensions can be readily prepared by nanoprecipitation.32 In addition to the frequently used 
poly(vinyl alcohol) (PVA) as stabilizer, a SHBP with the structure of  (DEAEMA50-c-
DEGDMA2)-b-(OEGMA80) was synthesized (Figure S6) and used as a stabilizer for PDI 
nanoparticles. 
 
Figure 2. Characterization of PDI nanoparticles prepared by nanoprecipitation with PVA and 
SHBP as stabilizer. (a) DLS profile of PDI nanoparticles prepared with PVA as stabilizer at the 
mass ratio of PDI:PVA = 1:1. (b) DLS profiles of PDI nanoparticles prepared with SHBP as 
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stabilizer at the mass ratio of PDI:SHBP = 2:1, 1:1, and 1:2. (c) UV-vis profiles of PDI 
nanoparticles prepared with PVA and SHBP as stabilizers at the mass ratio of PDI:stabilizer = 1:1. 
(d) The molecular structure and schematic representation of the SHBP. (e) The graph shows the 
relationship of the absorbance of PDI nanoparticles (PDI:SHBP = 1:1 w/w) at wavelength of 705 
nm versus PDI concentration, giving rise to a correlation equation y = 7.107x + 0.041, R2 = 0.9998. 
 
PDI nanoparticles were formed with both PVA and SHBP as stabilizers (at the mass ratio 
of PDI:stabilizer = 1:1), with particle diameters around 100 nm (in the range of 50 – 200 nm) as 
confirmed by dynamic laser scattering (DLS) analysis (Figure 2a, 2b). As seen in Figure 2c, the 
UV-Vis profiles of aqueous PDI nanoparticles with PVA and SHBP are similar. There is strong 
and broad absorbance in the range of 640 – 700 nm，similar to the profile obtained from the 
PDI-dichloromethane solution. More focused studies were carried out on the preparation of PDI 
nanoparticles using SHBP as stabilizer (Figure 2d) because it was found that PVA-stabilized PDI 
nanoparticles were not efficiently taken up by MSCs (discussed in section 3.3). Increasing the 
ratio of SHBP to PDI led to a narrower particle size distribution although the peak particle size 
was still around 100 nm (Figure 2b). The absorbance of PDI nanoparticles versus concentration 
was further investigated. As shown in Figure 2e, there was a linear concentration range of 0– 25 
mg/ml (0 – 0.37 mM), giving a molar extinction coefficient of 17,901 M-1 cm-1. For PDI 
nanoparticles with the mass ration of PDI:SHBP = 2:1, a higher molar extinction coefficient of 
19,110 M-1 cm-1 was achieved, which could be attributed to the higher content of PDI in the 
nanoparticle suspension. However, the shape of the UV-vis profiles for the PDI nanoparticles 
with both ratios of PDI:SHBP was very similar (Fig. S7). 
 
 14 
3.3. Biocompatibility and uptake of PDI nanoparticles in mouse MSCs. Mouse MSCs 
were labelled with varying concentrations of PDI nanoparticles with different stabilizers (SHBP 
and PVA, the mass ratio of PDI:stabilizer = 1:1) and tested in vitro to evaluate  how PDI 
nanoparticles would impact cell viability and uptake efficiency.  The mass ratio of PDI:stabilizer 
at 1:1 was selected for further investigation based on the balance of high nanoparticle stability 
and high PDI loading (hence higher extinction coefficient and signal intensity). 
The uptake of PDI nanoparticles by MSCs was first assessed by incubating with PDI 
nanoparticles for 24 hours and then carrying out UV-vis analysis of the labelled cell suspensions. 
There were no absorbance peaks observed for PDI nanoparticles prepared with PVA as stabilizer 
despite the blue appearance of the cell pellet after centrifugation (Figure 3a). This suggests that 
the PVA-stabilized nanoparticles were not taken up by the MSCs.  
The MSCs labelled with SHBP-stabilized PDI nanoparticles had absorbance around 700 
nm, with the intensity increasing as the dosing concentration was increased to 13.6 μg/ml (Figure 
3b). The peak intensity at 700 nm decreased when the PDI concentration was further increased to 
27.2 μg/ml. The high uptake of SHBP-stabilized PDI nanoparticles by MSCs can be attributed to 
the unique molecular structure of the SHBP (Figure 2d). The SHBP is comprised of many 
covalently cross-linked linear diblock copolymer chains containing both a hydrophobic section 
and a hydrophilic section which provides several advantages: multivalent stabilization, dendritic 
solubilization, and high molecular weight. While the hydrophobic section is anchored to the PDI 
nanoparticles to offer stabilization, the hydrophilic chains are likely to extend out from the 
nanoparticle surface to facilitate cell interactions and cell uptake.47 In comparison, a simple 
hydrophilic linear polymer chain, like the PVA used in this study, is weakly attached to the 
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hydrophobic nanoparticles. There is no polymer chains protruding from the particle surface to 
interact with the cells. Any excess PVA would be dissolved in the aqueous medium. 
The stability of PDI nanoparticles in cell culture medium (containing different ions and 
biomacromolecules) is highly important for biomedical studies.48 However, the characterization 
of PDI nanoparticles in culture medium in our study did not produce reliable results by DLS and 
electronic microscopy, which was likely due to the presence of biomacromolecules and the low 
atomic contrast between PDI nanoparticles and biomacromolecules (both organic). However, 
there was no observation of PDI nanoparticles aggregation during the culturing period, which 




Figure 3. In vitro evaluation of PDI nanoparticles by culturing with MSCs for 24 hours. UV-vis 
profiles of the MSC suspensions in PBS after culturing with PVA-stabilized PDI nanoparticles (a) 
and SHBP-stabilized PDI nanoparticles (b). (c) The flow cytometry analysis shows the intensity 
change of SHBP-PDI-labelled MSCs under the same culturing conditions as in (b). (d) Evaluation 
of cell cytoxicity based on ATP generation with SHBP-stabilized PDI nanoparticles. The bars 
indicate the mean value per group around the standard deviation (error bars, in the range of 0.6 – 
9.5 %, each experiment repeated 3 times). 
 
The fluorescence property of the PDI (fluorescence maxima wavelength 734 nm and 
quantum yield of 0.21 in CH2Cl2)
46 suggested that it was possible to characterize the presence of 
PDI nanoparticles by fluorescence-related techniques, e.g., flow cytometry. As such, the uptake 
of SHBP-stabilized PDI nanoparticles was further confirmed by analysis using flow cytometry, 
where an increase in intensity at 670 nm was observed with increasing dose concentration of PDI 
nanoparticles up to 13.6 μg/ml (Figure 3c). Further increase in PDI concentration (up to 27.2 
µg/ml) did not lead to further increases in intensity, indicating that the PDI concentration could 
be saturated beyond this point. This suggests that the uptake of PDI nanoparticles is optimal at 
13.6 μg/ml under our testing conditions, i.e., the highest uptake per unit cell. This concentration 
resulted in greater MSOT signal intensity because of the high uptake in the MSCs. Therefore, for 
all MSOT imaging experiments, MSC labelling was performed in the culture medium containing 
PDI nanoparticles (15 µg/ml, with the ratio of PDI:SHBP = 1:1 w/w). 
  The cytotoxicity of PDI nanoparticles when cultured with MSCs was assessed by the 
ATP assay against the MTT (3-[4,5-dimethylthiazol-2-diphenyl] tetrazolium bromide) assay. 
There were some issues with the MTT assay when testing the cytotoxicity of other nanoparticles 
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in previous studies,49 with the reason being mainly interference of the nanoparticles with the 
MTT assay components whilst ATP assay is accepted as the more sensitive, fast, and reliable 
method for evaluating cytotoxicity.50,51  MSCs were dosed with increasing concentrations of PDI 
nanoparticles (range 0 – 50 μg/ml) and their effect on cell health was assessed by measuring 
levels of ATP production.49 The initial assessments showed neither types of PDI nanoparticles 
had effect on ATP production with PDI nanoparticle concentrations up to 25 µg/ml. However, 
because of the low uptake of PVA-stabilized PDI nanoparticles by the MSCs, further studies 
were focused on SHBP-stabilized PDI nanoparticles. Figure 3d shows the ATP production of 
PDI-labelled MSCs was around 100% up to the PDI concentration of 25 µg/ml. The ATP 
production decreased considerably when the PDI concentration was increased further. 
Proliferation of the MSCs labelled with the PDI nanoparticles at the concentration of 25 µg/mL 
was compared with non-labelled MSCs. It was found that the proliferation of the MSCs was not 
negatively impacted by the uptake of PDI nanoparticles (Fig. S8), demonstrating the high 
biocompatibility of SHBP-stabilized PDI nanoparticles.  
 
3.4. Fate of PDI nanoparticles after uptake by MSCs. What happened to the PDI 
nanoparticle after being taken up by the MSCs is an important question. Did the PDI 
nanoparticles remain inside the MSCs or were they exocytosed into the medium? In the latter 
case, the result would show decreasing signal intensity in the cells due to there being fewer PDI 
nanoparticles.  This would suggest that the particles are not useful for cell tracking in vivo, 
because in addition to the reduced signal intensity, there could be problems with false positive 
results if the particles were taken up by host cells.  
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To investigate if there was any evidence of exocytosis, the MSCs labelled with PDI 
nanoparticles were co-cultured with non-labelled MSCs that expressed the green fluorescence 
protein, ZsGreen. If any of the ZsGreen-expressing cells were to become labelled with the PDI 
nanoparticles, this would suggest that the particles could be exocytosed and then taken-up by 
neighboring cells.  It was observed that none of the ZsGreen-expressing cells in the co-culture 
became labelled with PDI nanoparticles (Figure S9), indicating that the particles would be 
unlikely to generate false positive results in cell tracking experiments. 
To confirm that the PDI nanoparticles were not exocytosed from the MSCs, following 
labelling, MSCs were either left untreated (control group), or exposed to Mitomycin-C, which is 
a drug that prevents cells from proliferating. We would anticipate that over a few days, the 
fluorescence intensity of control MSCs would decrease, due to the nanoparticle load being 
reduced by 50% per cell with each cell division. On the other hand, in the Mitomycin-C treated 
non-proliferating cells, any loss in fluorescence could suggest that exocytosis was taking place.  
As shown in Figure 4a, for PDI-labelled MSCs without Mitomycin-C treatment, the fluorescence 
intensity of the cells has decreased significantly from the labelled cells (intensity 300) to 
culturing for 2 days (intensity 105) and for 4 days (intensity 10) whilst the fluorescence intensity 
for non-labelled cells is just 3. (Please note: The unit is arbitrary for the values of fluorescence 
intensity and these values are just for comparison purpose.). However, no loss of fluorescence 
intensity was observed in the Mitomycin-C treated group, even at 2 weeks following labelling 
(Figure 4b). Considering all these results, it suggests that the PDI nanoparticles are not 
exocytosed from the MSCs, thus confirming that the PDI nanoparticles are contained inside the 
MSCs after uptake. The reason is believed to be the stabilizing effect of SHBP on PDI 
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nanoparticles and strong interaction of SHBP with the surrounding environment after SHBP-
stabilized PDI nanoparticles are taken up by the MSCs.47 
 
Figure 4. Flow cytometry analysis of MSCs labelled with SHBP-stabilized PDI nanoparticles, 
which are further treated under different conditions. (a) The MSCs cultured in PDI-containing 
medium for 1 day (the ‘labelled’ sample), then further cultured in a fresh PDI-free medium for a 
further 24 h (sample ‘day 2’) or 72 h (sample ‘day 4’). (b) Labelled MSCs treated with Mitomycin-
C and then cultured in PDI-free medium for 14 days. Non-labelled MSCs are used as the control. 
 
3.5. Evaluation of PDI nanoparticles as PAI (MSOT) probes. The broad and strong 
NIR absorbance of PDI nanoparticles implies that they are suitable for PAI, particularly MSOT 
imaging. PDI-labelled MSCs were first imaged in a phantom with MSOT in order to show their 
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potential for in vivo imaging. MSC suspensions (PDI-labelled and non-labelled, 1 x 105 cells in 
150 µl PBS) were injected into channels within an agar phantom. The MSOT image clearly 
revealed the PDI-labelled MSCs (red) while the non-labelled cells could not be detected (Figure 
S10).  
 
Figure 5. Axial MSOT images of a mouse taken 1 day post-administration with PDI-labelled 
MSCs, where the red (a), yellow (b,c) and green circles (c) respectively indicate the spots 1 x 106, 
0.5 x 106 and 0.25 x 106 PDI-labelled MSCs. The white arrow indicates the position of non-labelled 
MSCs. The same length scale bar and colour scale bar are used for all the images. 
 
For in vivo imaging, PDI-labelled MSCs expressing Fluc and ZsGreen were injected 
subcutaneously into four locations in the flanks of the mouse. PDI-labelled MSCs were injected 
at the amounts of 1 x 106, 0.5 x 106 or 0.25 x 106 cells while non-labelled MSCs (1 x 106) were 
injected and served as a control. The torso of the mouse was imaged on day 1 in 1 mm intervals 
in a rostro-caudal direction. The PDI-labelled MSCs could be detected while no signal was 
detected from non-labelled MSCs (Fig. S11). Figure 5 shows representative MSOT images of the 
PDI-labelled MSCs. It is clear that the most intense signal was generated by the highest number 
of PDI-labelled MSCs (1 x 106 cells). However, the lowest number of PDI-labelled MSCs (0.25 
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x 106 cells) could still be detected by MSOT. The same scans were performed 7 and 11 days after 
injecting the labelled MSCs. MSOT images of similar quality on day 11 were obtained (Fig. S12, 
Fig. S13).  
 
Figure 6. MSOT 3D view of mouse after injection with MSCs on: a) day 1, b) day 7 and c) day 
11. Each panel shows the three cross-section view: top left, transverse plane; top right, sagittal 
plane; bottom left, coronal plane. Red circles indicate 1 x 106 PDI-labelled cells, yellow circles 
indicate 0.5 x 106 PDI-labelled cells, and green circles indicate 0.25 x 106 PDI-labelled cells. The 
cell locations are determined based on PDI signal intensity after spectrally unmixing. All these 
images utilise the same length scale bar and colour scale bar. 
 
3D images were created with the ViewMSOT software and three cross-sections are 
shown for each imaging times, i.e., day 1, day 7 and day 11, in Figure 6. The three injected PDI-
labelled MSC masses in the 3D views were observed at the expected locations in the mouse, with 
the highest number of injected cells giving the most intense signal throughout the imaging period 
from day 1 to day 11.  These results show the potential of the PDI nanoparticles as MSOT probes 
for long-term cell tracking. 
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Bioluminescence imaging was further used to confirm whether the cells were viable and 
proliferating. The strong and increasing signals over time by the luminescent radiance in Figure 
7a-c demonstrate that the PDI-labelled MSCs remained viable and were able to proliferate. It 
should be noted that in contrast to the MSOT images, the bioluminescence image is only planar 
and has poor spatial resolution. However, the use of bioluminescence was also essential for 
avoiding false positives in vivo. If the PDI-labelled MSCs were to undergo apoptosis, host 
macrophages would engulf the cell debris along with any released NPs, and hence a possibility 
of false positives by MSOT. If that happened, the bioluminescence signals from the MSCs would 
be lost or reduced. Since the bioluminescence signal intensity increased with time (Fig. 7a-c), 
this indicates it is unlikely to generate false positives upon cell death. 
 
Figure 7. Bioluminescence (a-c) and fluorescence imaging (d-f) of the mouse subcutaneously 
injected with MSCs: (a,d) day 1; (b,e) day 7; (c,f) day 11. Imaging spots: top left, non-labelled 
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MSCs; top right: PDI-labelled MSCs, 1 x 106 cells; bottom left, PDI-labelled MSCs, 0.5 x 106 
cells; bottom right, PDI-labelled MSCs, 0.25 x 106 cells.  
 
Since PDI nanoparticles also exhibit fluorescence properties, fluorescence imaging was 
employed to determine if the PDI-labelled MSCs generated sufficient signal to be detected by 
fluorescence imaging. On imaging of day 1, fluorescent spots were clearly visible for the two 
areas that were implanted with the larger numbers of PDI-labelled MSCs, with the area injected 
with 1 x106 PDI-labelled MSCs generating a more intense signal than the area injected with 0.5 x 
106 PDI-labelled MSCs (Figure 7d). For the area injected with the lowest number of cells (2.5 x 
105 cells), the signal could not be identified from background, indicating that in vivo 
fluorescence imaging of the PDI-labelled cells is not as sensitive as MSOT. As expected, no 
fluorescence signal was detected for the non-labelled MSCs (Figure 7d). Surprisingly, the 
fluorescence intensity increased with time (day 7 and day 11 imaging, Figures 7e-f) while there 
was still no signal from the non-labelled MSCs.  It is speculated that the bioluminescence 
released from the cells may enhance fluorescent intensity of the PDI nanoparticles via a 
bioluminescence resonance energy transfer (BRET) process (where small distance (≤ 10 nm) is 
required between bioluminescent donor and fluorescent acceptor)52 or a conventional radiating 
(where fluorescence is caused by unbound excitation from luminescence).53 In this event, the 
increasing bioluminescence from day 1 – day 11 would lead to intensified fluorescence signal. A 
control experiment, by fluorescence imaging of the implanted MSCs without firefly luciferase 
labelling, is proposed for future study and will be likely to confirm this explanation. Overall, 
these observations indicate that MSOT is superior to fluorescence imaging for indicating the 
precise position of PDI-labelled cells, and is also a more sensitive technique, as it enables fewer 
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numbers of cells to be detected than with fluorescence imaging. Ideally, for in vivo cell tracking, 
it is optimal to combine bioluminescence (firefly luciferase) with MSOT (PDI nanoparticles), 
because this allows the viability and proliferation of the cells to be monitored with 
bioluminescence, while at the same time allowing them to be precisely located with MSOT. 
 
 
Figure 8. Confocal microscope images of frozen sections of dissected MSC masses co-stained 
with DAPI (blue), where green colour is from ZsGreen expressing MSCs and red fluorescence is 
from PDI nanoparticles. (a) Non-labelled MSC masse does not show any red fluorescence; (b) 
PDI-labelled MSCs masse shows red fluorescence from PDI nanoparticles. The difference 
between non-labelled and labelled MSC masses is also visible in the composite image. 
Immunofluorescence was also carried out on frozen sections of dissected MSC masses, 
where the MSCs could be detected due to their expression of ZsGreen. Frozen sections (7 μm in 
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thickness) of the MSC masses were fixed with paraformaldehyde, stained with DAPI and imaged 
by confocal microscopy (Figure 8). The MSC mass derived from non-labelled MSCs did not 
display any red fluorescence whilst the MSC masses derived from PDI-labelled MSCs displayed 
a central area of red fluorescence. The yellowish feature in the composite image was also visible 
for PDI-labelled MSCs, as a result of composition with red fluorescence. This provides further 
evidence that staining of MSCs with PDI nanoparticles does not adversely affect cell 
proliferation and the imaging potential of PDI can be used for both MSOT and fluorescence 
imaging. 
MSCs were reported to show a propensity to differentiate into osteocytes and cartilage 
when injected subcutaneously into mice.54 Thus, in the present study, histological analysis was 
used to confirm the presence of calcium in both non-labelled and PDI-labelled samples, 




PDI nanoparticles as near-infrared absorbing probes are prepared and evaluated for in vivo tracking 
of MSCs using MSOT. The PDI nanoparticles are formed by nanoprecipitation using a star 
hyperbranched polymer (DEAEMA50-c-DEGDMA2)-b-(OEGMA80), with a particle size of around 
100 nm and good stability in aqueous medium. The PDI nanoparticles show excellent uptake into 
MSCs with no noticeable effect on cell viability up to concentrations of 25 µg/ml. The PDI-
labelled MSCs are injected into the flanks of mice where the probes can be clearly visualized up 
to 11 days post-administration with MSOT. The high sensitivity of MSOT allows for the detection 
of fewer numbers of cells than with fluorescence imaging. PDI nanoparticles can be used in 
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conjunction with bioluminescence imaging to assess cell viability and proliferation, in order to aid 
the development of regenerative medicine therapies. 
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